Last reviewed · How we verify
NCT06145932: rTMS
Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor
NA trial testing real rTMS in Essential Tremor in 40 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Second Affiliated Hospital of Soochow University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 7 November 2023 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- real rTMS
- sham rTMS
Conditions studied
- Essential Tremor — all drugs for Essential Tremor →
Sponsor
Second Affiliated Hospital of Soochow University
Who can join
Adults 18 to 80, any sex, with Essential Tremor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and electrophysiology of repetitive transcranial magnetic stimulation in the treatment of essential tremor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06145932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Essential Tremor
Currently open trials in the same condition.
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07172295 — Modulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With R · NA · recruiting
- NCT07016425 — Temporal Interference for Essential Tremor · NA · recruiting
- NCT07049003 — Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor · Phase 1 · recruiting
- NCT06428526 — Impact of Sensory Electrical Stimulation on Sensation and Tremor · NA · active not recruiting
Other Second Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07327411 — Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors · Phase 2 · not yet recruiting
- NCT07241897 — DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes · Phase 3 · not yet recruiting
- NCT07267234 — PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) · Phase 2 · not yet recruiting
- NCT07095790 — Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke · Phase 4 · recruiting
- NCT07002502 — Immune Modulation With PRaG-1 Treatment · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06145932 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Soochow University
- Last refreshed: 24 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing